Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | EDNRA | P25101 | 3/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.53 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | MME | P08473 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1580245 | 0.91 | PTGS1 (0.65) | PTGS1PTGS2 | |
| SCHEMBL9870799 | 0.88 | KMT2A (0.52) | KMT2AEDNRAPTGS1PTGS2MEN1 | |
| SCHEMBL7333442 | 0.81 | KMT2A (0.56) | KMT2AEDNRAALDH1A1MEN1HPGD | |
| SCHEMBL8791812 | 0.81 | EDNRA (0.55) | KMT2AEDNRAPTGS1PTGS2MAPK9 | |
| SCHEMBL805663 | 0.79 | PTGS1 (0.81) | KMT2APTGS1PTGS2MAPK9ALDH1A1 | |
| SCHEMBL9220209 | 0.79 | PTGS1 (0.81) | KMT2APTGS1PTGS2MAPK9ALDH1A1 | |
| SCHEMBL11459800 | 0.78 | MAPK9 (0.57) | KMT2AEDNRAPTGS1PTGS2MAPK9 | |
| SCHEMBL19416765 | 0.78 | PTGS1 (0.56) | PTGS1PTGS2 | |
| SCHEMBL8035766 | 0.78 | PTGS1 (0.59) | KMT2APTGS1PTGS2MAPK9ALDH1A1 | |
| SCHEMBL11296720 | 0.77 | EDNRA (0.49) | KMT2AEDNRAPTGS2ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2222645-B1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS FXR AGONISTS | HOFFMANN LA ROCHE (CH) | 2013-03-20 | — | — | EP | disclosed |
| US-8008503-B2 | Methyl-benzimidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-08-30 | — | — | US | disclosed |
| US-20100331371-A1 | METHYL-BENZIMIDAZOLE DERIVATIVES | BENSON GREGORY MARTIN | 2010-12-30 | — | — | US | disclosed |
| US-7825258-B2 | Methyl-benzimidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-20090131482-A1 | METHYL-BENZIMIDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2009-05-21 | — | — | US | disclosed |
| EP-1567498-B1 | MANDELIC ACID DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-01-23 | — | — | EP | disclosed |
| US-7129238-B2 | Mandelic acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-10-31 | — | — | US | disclosed |
| EP-1567498-A2 | MANDELIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-08-31 | — | — | EP | disclosed |
| US-20040122057-A1 | Novel mandelic acid derivatives | HOFFMANN-LA ROCHE INC. | 2004-06-24 | — | — | US | disclosed |
| WO-2004048335-A2 | MANDELIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122057-A1 | Novel mandelic acid derivatives | F7, F11, F9 | KMT2A 1963/4885EDNRA 598/4885PTGS1 1064/4885 |
| US-20090131482-A1 | METHYL-BENZIMIDAZOLE DERIVATIVES | HDAC10, CYP3A4, ECI1 | KMT2A 1135/4885EDNRA 2131/4885PTGS1 576/4885 |
| US-20100331371-A1 | METHYL-BENZIMIDAZOLE DERIVATIVES | HDAC10, CYP3A4, ECI1 | KMT2A 1135/4885EDNRA 2131/4885PTGS1 576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.